Dysregulation of glutamatergic circuits in the brain is involved in the development of centralized chronic pain.
NYX-2925 is in late stage clinical development across two chronic pain indications – Painful Diabetic Peripheral Neuropathy and Fibromyalgia.
Dysregulation of NMDA receptor-mediated processes may underlie the development and / or persistence of PTSD.
NYX-783 demonstrated clear signals of symptom reduction with a favorable tolerability profile in a Phase 2 exploratory study in patients with PTSD consisting of only 4 weeks of treatment with NYX-783; A registration-supportive study evaluating NYX-783 in patients with PTSD is expected to begin in 2021.
NYX-458 is a novel, oral, small molecule NMDA receptor modulator in development for the treatment of cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.
Lewy body dementia, consisting of dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) comprises 15–20% of cases of dementia.
NYX-458 is under evaluation in a first-in-patient Phase 2 study in cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.